Table 4.
Uni- and Multivariate Analysis for the Prediction of CSS
| Univariate Analysis |
Multivariate Analysis |
|||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| Cancer-specific survival | ||||||
| Age (≤75 y vs. >75 y) | 2.50 | 1.30-4.57 | 0.007 | 2.02 | 1.01-3.93 | 0.049 |
| Sex (male vs. female) | 1.19 | 0.59-2.22 | 0.591 | |||
| T-Stage (pT2 vs. p3-4) | 1.76 | 0.91-3.73 | 0.009 | 1.68 | 0.82-3.73 | 0.158 |
| Grade (G2 vs. 3-4) | 1.22 | 0.62-2.69 | 0.574 | |||
| Nodal-status (N0 vs. N+) | 2.32 | 1.29-4.15 | 0.006 | 1.80 | 0.89-3.70 | 0.105 |
| LVI | 1.84 | 1.05-3.344 | 0.033 | 1.38 | 0.66-2.74 | 0.401 |
| Concomitant carcinoma in situ | 1.34 | 0.68-2.95 | 0.408 | |||
| Adjuvant chemotherapy | 0.79 | 0.36-1.97 | 0.587 | |||
| Micropapillary | 1.50 | 0.61-3.13 | 0.343 | |||
| Subtype | 0.003 | 0.023 | ||||
| Separate multivariate models each with inclusion of the above values and a single a pair of subtypes | ||||||
| Her2 vs. Luminal A | 4.43 | 1.57-18.55 | 0.0208 | 4.41 | 1.53-18.71 | 0.004 |
| Her2 vs. Luminal B | 1.54 | 0.82-3.06 | 0.180 | 1.96 | 0.99-4.08 | 0.053 |
| Her2 vs. Triple neg. | 2.28 | 0.81-9.53 | 0.123 | |||
| Luminal A vs. Luminal B | 0.34 | 0.07-1.07 | 0.062 | 0.44 | 0.10-1.39 | 0.174 |
| Luminal A vs. Triple neg | 0.51 | 0.09-2.77 | 0.419 | |||
| Luminal B vs. Triple neg | 1.47 | 0.48-6.45 | 0.523 | |||